Chr. Hansen to showcase latest poultry probiotics research at IPPE
Studies show broilers fed probiotics maintain performance on energy-reduced diets.
Studies show broilers fed probiotics maintain performance on energy-reduced diets.
Today, Chr. Hansen and Caelus Health announce their collaboration on the development of Eubacterium hallii as a next generation probiotic for prevention and treatment of metabolic disease.
At Chr. Hansen, the animal health and nutrition business supplies probiotics to various customers in the global livestock industry. Through the acquisition of US-based Nutritional Physiology Company (NPC), Chr. Hansen will further broaden this microbial platform and expand its presence into the beef cattle segment.
Millions of people around the world suffer from a range of gastrointestinal symptoms. Results from one of the world’s largest clinical studies on probiotics now show that the probiotic strain named BB-12® can be part of the solution by improving bowel regularity.
With the completion and publication of the world’s largest clinical study on the immune effect of probiotics in adults, Chr. Hansen has obtained results indicating that the probiotic strain named L. CASEI 431® can shorten the duration of common cold and influenza-like illness, lower the use of health care resources and reduce use of antibiotics.
Chr. Hansen launches ‘Mother’s 1st‘, a convenient soft gel supplement combining probiotics and omega-3. Mother’s 1st is developed specifically to support immune and gut health in pregnant and lactating women as well as early brain and eye development in infants.
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.